相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs
Giulia Berno et al.
BMC MEDICAL GENETICS (2014)
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms
Antonio D'Avolio et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Psychosocial Predictors of Non-Adherence and Treatment Failure in a Large Scale Multi-National Trial of Antiretroviral Therapy for HIV: Data from the ACTG A5175/PEARLS Trial
Steven A. Safren et al.
PLOS ONE (2014)
Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers
Kyoung-Ah Kim et al.
PHARMACOGENETICS AND GENOMICS (2014)
Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide)
Elaine Tseng et al.
DRUG METABOLISM AND DISPOSITION (2014)
ABCB1 Variation and Treatment Response in AIDS Patients: Initial Results of the Henan Cohort
Peng Zhu et al.
PLOS ONE (2013)
Discordant Associations Between SLCO1B1 521T → C and Plasma Levels of Ritonavir-boosted Protease Inhibitors in AIDS Clinical Trials Group Study A5146
Xinyan Zhang et al.
THERAPEUTIC DRUG MONITORING (2013)
A Population Pharmacokinetic-Pharmacogenetic Analysis of Atazanavir
Deidre A. Kile et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2012)
Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients
R. M. Savic et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Antiretroviral Treatment of Adult HIV Infection 2012 Recommendations of the International Antiviral Society-USA Panel
Melanie A. Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings
Thomas B. Campbell et al.
PLOS MEDICINE (2012)
Atazanavir Metabolism According to CYP3A5 Status: An In Vitro-In Vivo Assessment
Michael F. Wempe et al.
DRUG METABOLISM AND DISPOSITION (2011)
Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study
Rubin Lubomirov et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance
Alessandro Schipani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men
Fabiana B. Kohlrausch et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Using Different Calculations of Pharmacy Refill Adherence to Predict Virological Failure Among HIV-Infected Patients
I. Marion de Boer et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study
Heather J. Ribaudo et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients
D. R (Niel) Malan et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors
Peter L. Anderson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Effect of CYP3A5 Genotype on Renal Allograft Recipients Treated With Tacrolimus
J. S. Chen et al.
TRANSPLANTATION PROCEEDINGS (2009)
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir
Marco Siccardi et al.
CLINICAL INFECTIOUS DISEASES (2008)
Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients
Caroline Solas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN study (AI424-097) 48-week results
Jose Gatell et al.
CLINICAL INFECTIOUS DISEASES (2007)
CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir
F. Josephson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Assessing antiretroviral adherence via electronic drug monitoring and self-report: An examination of key methodological issues
Cynthia R. Pearson et al.
AIDS AND BEHAVIOR (2007)
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV
Qing Ma et al.
PHARMACOGENOMICS (2007)
A silent polymorphism in the MDR1 gene changes substrate specificity
Chava Kimchi-Sarfaty et al.
SCIENCE (2007)
Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects
Kyoung-Ah Kim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: A pilot study
Peter L. Anderson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Clinical implications of CYP3A polymorphisms
Leszek Wojnowski et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2006)
Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir:: An adult AIDS clinical trials group study
DW Haas et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Atazanavir: Effects on P-glycoprotein transport and CYP3A metabolism in vitro
ES Perloff et al.
DRUG METABOLISM AND DISPOSITION (2005)
Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics
M Fröhlich et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV
K Squires et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
CYP3A variation and the evolution of salt-sensitivity variants
EE Thompson et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nlfinavir or atazanavir
R Wood et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Basic statistics and the inconsistency of multiple comparison procedures
DJ Saville
CANADIAN JOURNAL OF EXPERIMENTAL PSYCHOLOGY-REVUE CANADIENNE DE PSYCHOLOGIE EXPERIMENTALE (2003)
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
DA Hesselink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects
I Sanne et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2003)
A comparison of Bayesian methods for haplotype reconstruction from population genotype data
M Stephens et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
J Fellay et al.
LANCET (2002)
The genetic determinants of the CYP3A5 polymorphism
E Hustert et al.
PHARMACOGENETICS (2001)
A new statistical method for haplotype reconstruction from population data
M Stephens et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
分享论文
